Journal of the Operational Research Society

, Volume 60, Issue 4, pp 506–518

The cost-effectiveness of surgical instrument management policies to reduce the risk of vCJD transmission to humans

Case-Oriented Paper

Abstract

Current sterilization techniques may not be completely effective at removing prions from surgical instruments, which can then infect patients on whom these instruments are subsequently used. This risk is increased due to the current level of instrument migration. With wide uncertainty in the numbers of patients that are incubating variant Creutzfeldt–Jakob disease (vCJD) and effectiveness of decontamination, the UK is facing a potentially self-sustaining epidemic, which could be averted with the introduction of single-use instruments. This paper focuses on the cost-effectiveness of management strategies concerning the introduction of single-use instruments and measures to prevent migration. We formulated a discrete event simulation model of the dynamics of infection transmission, surgical instrument contamination and migration, to produce results that were pivotal in shaping government policy. Field data about vCJD transmission has then been used to update cost-effectiveness assessments as part of a retrospective analysis, which reinforces the initial decision.

Keywords

simulation cost benefit analysis hospitals variant Creutzfeldt–Jakob disease (vCJD) replacement Bayesian inference 

References

  1. Andrews NJ (2007). Incidence of variant Creutzfeldt–Jakob disease diagnoses and deaths in the UK January 1994–December 2007. Available from http://www.cjd.ed.ac.uk/cjdq56.pdf.
  2. Baxter RL, Baxter HC, Campbell GA, Grant K, Jones A, Richardson P and Whittaker G (2006). Quantitative analysis of residual protein contamination on reprocessed surgical instruments. J Hosp Infect 63(4): 439–444.CrossRefGoogle Scholar
  3. Bennett P, Hare A and Townshend J (2005). Assessing the risk of vCJD transmission via surgery: Models for uncertainty and complexity. J Opl Res Soc 56: 202–213.CrossRefGoogle Scholar
  4. Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson V, Tuzi N, Head M, Ironside J and Will R (2006). Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 5(5): 393–398.CrossRefGoogle Scholar
  5. Brennan A, Chick SE and Davies R (2006). A taxonomy of model structures for economic evaluation of health technologies. Health Econ 15: 1295–1310.CrossRefGoogle Scholar
  6. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H and Bostock CJ (1997). Transmissions to mice indicate that ‘new variant' CJD is caused by the BSE agent. Nature 389(6650): 498–501.CrossRefGoogle Scholar
  7. Bruce ME, McConnell I, Will RG and Ironside JW (2001). Detection of variant Creutzfeldt–Jakob disease infectivity in extraneural tissues. Lancet 358(9277): 208–209.CrossRefGoogle Scholar
  8. Chick SE (2001). Input distribution selection for simulation experiments: Accounting for input uncertainty. Opns Res 49(5): 744–758.CrossRefGoogle Scholar
  9. Clarke P and Ghani AC (2005). Projections of the future course of the primary vCJD epidemic in the UK: Inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface 2: 19–31.CrossRefGoogle Scholar
  10. Currie CSM, Williams BG, Cheng RC and Dye C (2003). Tuberculosis epidemics driven by HIV: Is prevention better than cure? AIDS 17: 2501–2508.CrossRefGoogle Scholar
  11. Davies R, Roderick P and Raftery J (2003). The evaluation of disease prevention and treatment using simulation models. Eur J Opns Res 150: 53–66.CrossRefGoogle Scholar
  12. Department of Health (2006a). Assessing the risk of vCJD transmission via surgery. An interim review. Econ Stat Opl Res (cited 10/11/06). Available from http://www.dh.gov.uk/assetRoot/04/11/35/42/04113542.pdf.
  13. Department of Health (2006b). Chief Executive Bulletin Issue 37 (cited 10/11/06). Available from http://www.publications.doh.gov.uk/cebulletin19oct.htm#1.
  14. Fenwick E, Claxton K and Sculpher M (2001). Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ 10: 779–787.CrossRefGoogle Scholar
  15. Garske T, Clarke PS, Ward H, Will RG and Ghani AC (2006). Factors determining the potential for onward transmission of vCJD via surgical instruments. J R Soc Interface 3(11): 757–766.CrossRefGoogle Scholar
  16. Geweke J (1989). Bayesian inference in econometric models using Monte Carlo integration. Econometrica 57(6): 1317–1339.CrossRefGoogle Scholar
  17. Ghani AC, Ferguson NM, Donnelly CA and Anderson RM (2003). Factors determining the pattern of the variant Creutzfeldt–Jakob disease (vCJD) epidemic in the UK. Proc Roy Soc Ser B 270: 689–698.CrossRefGoogle Scholar
  18. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, Penney M, Hegazy D and Ironside JW (2004). Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 203: 733–739.CrossRefGoogle Scholar
  19. Hospital Episode Statistics (2006) (cited 01/09/06). Available from http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=192.
  20. Inglehart DL (1975). Simulating stable stochastic systems, V: Comparison of ratio estimators. Naval Res Logist Quart 22: 553–565.CrossRefGoogle Scholar
  21. Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, Le Grice M, Ritchie DL, McCardle LM and Hilton DA (2006). Variant Creutzfeldt–Jakob disease: Prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 332(7551): 1186–1188.CrossRefGoogle Scholar
  22. Jacquez JA (1996). Compartmental Analysis in Biology and Medicine, 3rd edn.. BioMedWare: Ann Arbor, Michigan, USA.Google Scholar
  23. Llewelyn CA, Hewitt PE, Knight RSG, Amar K, Cousens S, Mackenzie J and Will R (2004). Possible transmission of variant Creutzfeldt–Jakob disease by blood transfusion. Lancet 363: 417–421.CrossRefGoogle Scholar
  24. Merrick JRW, van Dorp JR and Dinesh V (2005). Assessing uncertainty in simulation based maritime risk assessments. Risk Anal 25(3): 731–743.CrossRefGoogle Scholar
  25. National Institute of Clinical Excellence (2004). Guide to the Methods of Technology Appraisal. Draft for consultation November 2007. Cited 20/02/08. National Institute of Clinical Excellence. Available from http://www.nice.org.uk/media/8AE/5C/TAMethodsguideUpdateFinalforConsultation281107.pdf.
  26. National Institute for Health and Clinical Excellence (2006). Patient safety and the risk of transmission of Creutzfeldt–Jakob disease (CJD) via interventional procedures (cited 25/11/06). Available from http://www.nice.org.uk/guidance/IPG196/guidance/pdf/English.
  27. Office for National Statistics (2006). Interim Life Tables, United Kingdom 2003–2005 http://www.statistics.gov.uk/STATBASE/Product.asp?vlnk=14459.
  28. O'Hagan A, Buck CE, Daneshkhah A, Eiser JE, Garthwaite PH, Jenkinson DJ, Oakley JE and Rakow T (2006). Uncertain Judgements: Eliciting Experts' Probabilities, 1st edn.. John Wiley and Sons: Chichester.CrossRefGoogle Scholar
  29. Peden AH, Head MW, Ritchie DL, Bell JE and Ironside JW (2004). Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364(9433): 527–529.CrossRefGoogle Scholar
  30. Pharmaceutical Journal (2004). Preclinical vCJD: Prevalence higher than expected. Pharm J 272(7301): 663.Google Scholar
  31. Rauner MS, Brailsford SC and Flessa S (2005). Use of discrete-event simulation to evaluate strategies for the prevention of mother-to-child transmission of HIV in developing countries. J Opl Res Soc 56: 222–233.CrossRefGoogle Scholar
  32. Stevenson M, Oakley J and Chick SE (2006). Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease (CJD) via interventional procedures—final report (second consultation) (cited 01/09/06). Available from http://www.nice.org.uk/guidance/IPG196/.
  33. Taylor DM, Fraser H, McConnell I, Brown DA, Brown KL, Lamza KA and Smith GRA (1994). Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol 139(3–4): 313–326.CrossRefGoogle Scholar
  34. The National Creutzfeldt–Jakob Disease Surveillance Unit, Edinburgh (2007). CJD Statistics (cited 22/08/2007). http://www.cjd.ed.ac.uk/figures.htm.
  35. The Royal College of Surgeons for England (2006). National Prospective Tonsillectomy Audit (cited 10/11/06). Available http://www.entuk.org/members/audits/tonsil/Tonsillectomyauditreport_pdf.
  36. Tomkinson A, De Martin S, Gilchrist CR and Temple M (2005). Instrumentation and patient characteristics that influence postoperative haemorrhage rates following tonsil and adenoid surgery. Clin Otolaryngol 30: 338–346.CrossRefGoogle Scholar
  37. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C and Luce BR (2003). Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices—Modeling studies. Value in Health 6(1): 9–17.CrossRefGoogle Scholar
  38. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A and Smith PG (1996). A new variant of Creutzfeldt–Jakob disease in the UK. Lancet 347(9006): 921–925.CrossRefGoogle Scholar
  39. Zouaoui F and Wilson JR (2003). Accounting for parameter uncertainty in simulation input modeling. IIE Trans 35: 781–792.CrossRefGoogle Scholar

Copyright information

© Palgrave Macmillan 2008

Authors and Affiliations

  • M D Stevenson
    • 1
  • J E Oakley
    • 2
  • S E Chick
    • 3
  • K Chalkidou
    • 4
  1. 1.School of Health and Related Research, University of SheffieldSheffieldUK
  2. 2.Department of Probability and StatisticsUniversity of SheffieldSheffieldUK
  3. 3.Technology and Operations Management Area, INSEADFontainebleauFrance
  4. 4.National Institute for Health and Clinical ExcellenceLondonUK

Personalised recommendations